Loading...
Loading...
IKT| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 6.6K |
| Gross Profit | -6.6K |
| Operating Expense | 5,044.0K |
| Operating I/L | -5,050.5K |
| Other Income/Expense | 90.9K |
| Interest Income | 90.9K |
| Pretax | -4,959.6K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -4,959.6K |
Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company specializing in the development of therapeutics for Parkinson's Disease (PD) and related disorders. The company's product candidates, including IkT-148009 and IkT-001Pro, target PD symptoms and gastrointestinal complications, as well as blood and stomach cancers. Inhibikase Therapeutics generates revenue through the development and potential commercialization of these product candidates. The company also engages in research programs for other neurological diseases and has research and development collaborations with several prominent universities.
